Publicaciones en colaboración con investigadores/as de Boston University School of Medicine (30)

2024

  1. Can gait patterns be explained by joint structure in people with and without radiographic knee osteoarthritis? Data from the IMI-APPROACH cohort

    Skeletal Radiology, Vol. 53, Núm. 11, pp. 2409-2416

2023

  1. Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance

    Arthritis Care and Research, Vol. 75, Núm. 1, pp. 53-60

  2. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries

    Annals of the rheumatic diseases, Vol. 82, Núm. 5, pp. 698-709

  3. Exploring the differences between radiographic joint space width and MRI cartilage thickness changes using data from the IMI-APPROACH cohort

    Skeletal Radiology, Vol. 52, Núm. 7, pp. 1339-1348

  4. Machine-learning predicted and actual 2-year structural progression in the IMI-APPROACH cohort

    Quantitative Imaging in Medicine and Surgery, Vol. 13, Núm. 5, pp. 3298-3306

  5. Quantitative CT of the knee in the IMI-APPROACH osteoarthritis cohort: Association of bone mineral density with radiographic disease severity, meniscal coverage and meniscal extrusion

    Bone, Vol. 168

  6. Test–retest precision and longitudinal cartilage thickness loss in the IMI-APPROACH cohort

    Osteoarthritis and Cartilage, Vol. 31, Núm. 2, pp. 238-248

2022

  1. Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry

    ACR Open Rheumatology, Vol. 4, Núm. 11, pp. 948-953

  2. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

    Annals of the rheumatic diseases, Vol. 81, Núm. 7, pp. 970-978

  3. Development of a Prediction Model for COVID-19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry

    ACR Open Rheumatology, Vol. 4, Núm. 10, pp. 872-882

  4. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

    The Lancet Rheumatology, Vol. 4, Núm. 9, pp. e603-e613

  5. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

    RMD Open, Vol. 8, Núm. 2

  6. Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera

    Annals of the Rheumatic Diseases

  7. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: Results from the COVID-19 Global Rheumatology Alliance provider registry

    RMD Open, Vol. 8, Núm. 1

  8. Structural tissue damage and 24-month progression of semi-quantitative MRI biomarkers of knee osteoarthritis in the IMI-APPROACH cohort

    BMC Musculoskeletal Disorders, Vol. 23, Núm. 1

2021

  1. Association between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death among Patients with Immune-Mediated Inflammatory Disease and COVID-19

    JAMA Network Open

  2. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 9, pp. 1137-1146

  3. Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases

    The Lancet Rheumatology, Vol. 3, Núm. 10, pp. e707-e714

  4. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

    The Lancet Rheumatology, Vol. 3, Núm. 12, pp. e855-e864

2020

  1. Subcutaneous tanezumab for osteoarthritis of the hip or knee: Efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 6, pp. 800-810